iSERA Lifesciences Reports Q2 FY27 Results with Continued Net Losses
iSERA Lifesciences Ltd · Financial Result · 04 Nov 2026, 11:13 pm
iSERA Lifesciences Reports Q2 FY27 Results with Continued Net Losses iSERA Lifesciences Limited reported nil revenue from operations for the quarter ended 30th Sep'26, matching Q1 FY27 and Q2 FY26. Total income stood at ₹7.88 lakh, derived entirely from other income. Total expenses reached ₹20.99 lakh compared to ₹33.62 lakh in Q1 FY27 and ₹0.30 lakh in Q2 FY26. The company posted a net loss of ₹13.11 lakh versus a loss of ₹33.62 lakh in Q1 FY27 and a profit of ₹0.70 lakh in Q2 FY26. Quarterly basic and diluted EPS was negative ₹0.62.
Original exchange filing (PDF)
More announcements from iSERA Lifesciences Ltd
- Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Administrative Warning Letter received .... · 15 Nov 2026
- Dissemination of Warning Letter of SEBI · 12 Nov 2026
- We hereby submit the revised un-Audited Financial result for Half year ended September 2026 under regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 · 05 Nov 2026
- We hereby submit that pursuant to Regulation 15(2) of SEBI (LODR) Regulations, 2015, the compliance with the corporate governance provisions as specified in Regulations 17, 18, 19, 20, .... · 04 Nov 2026
- Outcome of the Board Meeting held today on 4th November 2026 under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 · 04 Nov 2026
- Isera Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve the Un-Audited Financial .... · 04 Nov 2026
- Disclosure under Regulation 7(2) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 - Continual Disclosure consequent to Preferential Allotment of .... · 09 Oct 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Archana Lonkar · 07 Oct 2026
